A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|11|1647-1655

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.11, 2014-06, pp. : 1647-1655

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 976-982

John Wiley & Sons Inc

Access to resources Recommend Favorite

Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional Study

By  

Oncology Research and Treatment, Vol. 36, Iss. 3, 2013-02 ,pp. : 95-100

Karger

Access to resources Recommend Favorite

Ramucirumab in metastatic renal cell carcinoma: The beginning or the end?

By  

CANCER, Vol. 120, Iss. 11, 2014-06 ,pp. : 1604-1607

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 3024-3031

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ramucirumab in metastatic renal cell carcinoma: The sex, race, and age issues

By  

CANCER, Vol. 120, Iss. 15, 2014-08 ,pp. : 2379-2379

John Wiley & Sons Inc

Access to resources Recommend Favorite